Home' Australian Pharmacist : Australian Pharmacist October 2014 Contents Australian Pharmacist October 2014 I ©Pharmaceutical Society of Australia Ltd. 73
The transformation of
Transformation of the pharmacy sector
will be a key focus at the premier
conference for the non-prescriptions
industry this year -- the Australian Self
Medication Industry (ASMI) Conference on
An array of international and local speakers
will explore some of the major issues
impacting pharmacy and the healthcare
consumer. Local speakers will share new
research on issues critical to the future of
pharmacy in Australia, and international
speakers will share global insights and
Keynote presentations will include research
into extending the role of the pharmacist;
case studies highlighting best practice
healthcare retailing; the latest evidence
from Macquarie University on consumer
healthcare behaviour; new research to
support the preventative use of certain
complementary medicines; the uptake of self
care to help build a more sustainable health
system, and TGA's update on the status of
current regulatory reform.
supplements can play in preventative
health. This research is based on rigorous
scientific evidence of the efficacy of specific
complementary medicines identified in
Self care is gaining traction as governments
worldwide struggle with how to build more
sustainable healthcare systems. On the eve
of the launch of the Self Care Alliance in
Australia, Gopa Mitra, a founding member
of the UK Self Care Forum, will share insights
on how the UK has addressed self care
to alleviate pressure on the UK's ailing
Finally, delegates will hear from the TGA's
Dr Lisa Studdert, who will give an update
on the status of regulatory reforms of
importance to the non-prescription
medicines industry, in particular, labelling,
advertising and scheduling.
ASMI has a special Healthcare Professional
(e.g. doctor, pharmacist, nurse, naturopath)
and pharmacy assistant rate of only $695
for the conference (day only) and if you
register five or more people you receive an
additional 10% discount. More details about
the event and registration information can
be found at: www.asmi.com.au/events.
1. Department of Health and Ageing. Review of anticoagulation
therapies in atrial fibrillation. Final report. 2012 [cited 2013
7/02/2013]; At: www.pbs.gov.au/info/publication/factsheets/
2. Bereznicki LR, Peterson GM, Jackson SL, et al. The risks
of warfarin use in the elderly. Expert Opin Drug Saf
3. Jackson SL, Peterson GM, Vial JH, et al. Outcomes in the
management of atrial fibrillation: Clinical trial results can
apply in practice. Intern Med J 2001;31:329--36.
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus
warfarin in patients with atrial fibrillation. N Engl J Med
5. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus
warfarin in nonvalvular atrial fibrillation. N Engl J Med
6. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban
versus warfarin in patients with atrial fibrillation. N Engl J Med
7. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus
warfarin in patients with atrial fibrillation. N Engl J Med
8. Atrial Fibrillation Investigators. Risk factors for stroke and
efficacy of antithrombotic therapy in atrial fibrillation. Analysis
of data from five randomised controlled trials. Arch Intern
9. Lip GY. Thromboprophylaxis for atrial fibrillation. Lancet 1999;
10. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical
classification schemes for predicting stroke - results from the
national registry of atrial fibrillation. JAMA 2001;285:2864--70.
11. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting
stroke or death in individuals with new-onset atrial fibrillation
in the community: The framingham heart study. JAMA
12. Gage BF, van Walraven C, Pearce L, et al. Selecting
patients with atrial fibrillation for anticoagulation: Stroke
risk stratification in patients taking aspirin. Circulation
13. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update
of the esc guidelines for the management of atrial fibrillation:
An update of the 2010 ESC guidelines for the management
of atrial fibrillation * developed with the special contribution
of the european heart rhythm association. Euro Heart J
14. Bereznicki LR, Peterson GM. New antithrombotics for atrial
fibrillation. Cardiovasc Ther 2010;28:278--86.
15. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics,
pharmacodynamics and tolerability of dabigatran etexilate, a
new oral direct thrombin inhibitor, in healthy male subjects.
Br J Clin Pharmacol 2007; 64:292--303.
16. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs:
American college of chest physicians evidence-based clinical
practice guidelines (8th edition). Chest 2008;133:234S--56S.
17. Potpara TS, Lip GY, Apostolakis S. New anticoagulant
treatments to protect against stroke in atrial fibrillation. Heart
18. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients
with atrial fibrillation. N Engl J Med 2011;364:806--17.
19. Salazar CA, del Aguila D, Cordova EG. Direct thrombin
inhibitors versus vitamin k antagonists for preventing cerebral
or systemic embolism in people with non-valvular atrial
fibrillation. Cochrane Database Syst Rev 2014;3:CD009893.
20. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of
the efficacy and safety of new oral anticoagulants with
warfarin in patients with atrial fibrillation: A meta-analysis of
randomised trials. Lancet 2014;383:955--62.
21. Liew A, O'Donnell M, Douketis J. Comparing mortality in
patients with atrial fibrillation who are receiving a direct-
acting oral anticoagulant or warfarin: A meta-analysis of
randomized trials. J Thromb Haemost 2014.
22. Bruins Slot KM, Berge E. Factor xa inhibitors versus vitamin k
antagonists for preventing cerebral or systemic embolism in
patients with atrial fibrillation. Cochrane Database Syst Rev
23. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in
elderly patients. Arch Intern Med 2011;171:1285--6.
24. Wood S. Deaths prompt dabigatran safety advisory
in japan. Heartwire. At: www.medscape.com/
25. Wall T. Pradaxa deaths probed. stuff.co.nz. At: www.stuff.
26. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control
and prediction of adverse events in patients with atrial
fibrillation: A systematic review. Circ Cardiovasc Qual
27. Wieloch M, Sjalander A, Frykman V, et al. Anticoagulation
control in sweden: Reports of time in therapeutic range,
major bleeding, and thrombo-embolic complications
from the national quality registry auricula. Euro Heart J
28. Bereznicki LR, Madden AR, Peterson GM. The quality of
international normalised ratio control in southern tasmania.
Med J Aust 2013;198:315.
29. National Institute for Health and Care Excellence (NICE). Atrial
fibrillation: The management of atrial fibrillation (cg180). UK:
30. Pottegard A, Poulsen BK, Larsen MD, et al. Dynamics of
vitamin k antagonist and new oral anticoagulants use in
atrial fibrillation: A danish drug utilization study. J Thromb
31. Cohen D. Dabigatran: How the drug company withheld
important analyses. BMJ 2014;349:g4670.
32. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin
in patients with atrial fibrillation: A report from the swedish
atrial fibrillation cohort study. Circulation 2012;125:2298--307.
33. January CT, Wann LS, Alpert JS, et al. 2014 aha/acc/hrs
guideline for the management of patients with atrial
fibrillation: A report of the american college of cardiology/
american heart association task force on practice guidelines
and the heart rhythm society. J Am Coll Cardiol 2014.
34. Australian Medicines Handbook. Australian medicines
handbook. Rossi S, ed. Adelaide: Australian Medicines
Global retailing expert, Steve Sowerby,
will share global best practice in healthcare
retailing, spotlighting retailers who have
successfully transformed their pharmacies
into health destinations. Delegates will
also hear from Dr Alison Roberts, of the
Pharmaceutical Society of Australia,
who will present findings of the Health
Destination Pharmacy Trial, teasing out
learnings and implications as Australian
pharmacy moves towards a new model.
International speaker Nicholas Hall
will provide global insights and trends
in consumer healthcare based on his
40 year international experience in the
field, and Macquarie University Professor,
Scott Koslow, will reveal new research on
the healthcare consumer and how their
current and future behaviour can unlock
savings to healthcare budgets and expand
the role pharmacy plays in this mix.
Complementary medicines are the largest
and fastest growing consumer healthcare
products segment in Australia and
overseas. Steve Mister from the Council
for Responsible Nutrition in Washington
will outline research which supports
the valuable role certain vitamins and
References from What Drug article page 66.
Links Archive Australian Pharmacist September 2014 Australian Pharmacist November 2014 Navigation Previous Page Next Page